Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 2/3 2Phase 1 2Phase 4 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Burkitt Lymphoma 1Agnosia 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 15Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Radiotherapy 10Nivolumab 10Bevacizumab 10atezolizumab 8Radiation 8Platinum 8Pemetrexed 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Drug Therapy 7Dexamethasone 7Temozolomide 6Rituximab 6Radiotherapy, Intensity-Modulated 6Prednisone 6Surgical Procedures, Operative 5Ipilimumab 5Immunoglobulin G 5Disulfides 5Cytarabine 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Acetaminophen × 90 days × Clear all
NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT05597878 2026-06-01

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Wake Forest University Health Sciences

Phase 2/3 Terminated
58 enrolled
Genitourinary

Agnosia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡